Chlamydia mRNA vaccine study for adults 18-29
Part of Infections clinical trials.
This study tests a new mRNA vaccine designed to prevent chlamydia infection. It is for adults aged 18 to 29 who have a higher risk of getting chlamydia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 29 years old.
- You have a higher risk of getting chlamydia (e.g., new sex partner, multiple partners, inconsistent condom use).
- If you are a woman, you are not pregnant or breastfeeding and you use effective birth control (or are surgically sterile).
- You do not currently have chlamydia or gonorrhea (must test negative).
- You do not have serious health conditions like HIV, hepatitis B/C, a weakened immune system, heart inflammation, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines how your body's immune system responds to a Chlamydia trachomatis infection by analyzing urine and blood samples. Researchers hope to better understand infection patterns and improve future treatments.
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
This trial tests new mRNA-based flu vaccines that may provide broader protection against different flu strains. Participants will receive the vaccine and be monitored for safety and their immune response.
This study tests a new shingles vaccine (called an mRNA vaccine) given as a shot. It aims to prevent shingles in adults aged 40 and above. If you qualify, you may receive the vaccine or a placebo, and your health will be monitored for a period of time.
Hear when a new Chlamydia Trachomatis Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.